10 August 2026
1QFY27 Results Update | Sector: Healthcare

Gland Pharma

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	GLAND IN
Equity Shares (m)	165
M.Cap.(INRb)/(USDb)	440 / 4.6
52-Week Range (INR)	2685 / 1574
1, 6, 12 Rel. Per (%)	6/47/37
12M Avg Val (INR M)	699

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	64.3	72.6	83.2
EBITDA	16.3	19.5	23.2
Adj. PAT	10.4	12.7	15.4
EBITDA Margin (%)	25.3	26.9	27.9
Cons. Adj. EPS (INR)	63.4	76.9	93.2
EPS Gr. (%)	49.6	21.2	21.3
BV/Sh. (INR)	628.7	705.5	798.7
Ratios			
Net D:E	(0.3)	(0.3)	(0.4)
RoE (%)	10.7	11.5	12.4
RoCE (%)	10.6	11.3	12.2
Payout (%)	0.0	0.0	0.0
Valuations			
P/E (x)	42.0	34.6	28.6
EV/EBITDA (x)	25.0	20.7	16.9
Div. Yield (%)	0.0	0.0	0.0
FCF Yield (%)	1.2	0.2	2.3
EV/Sales (x)	6.3	5.6	4.7

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	51.8	51.8	51.8
DII	30.4	33.4	32.9
FII	8.7	7.3	7.4
Others	9.1	7.5	7.9

FII Includes depository receipts

CMP: INR2,667 **TP: INR3,080 (+15%)** **Buy**

US, EU strength drives 5-9% beat

Full-service CDMO pact improves growth outlook

- Gland Pharma (GLAND) delivered a better-than-expected financial performance in 1QFY27, with 5%/9%/9% beat on revenue/EBITDA/PAT. The performance was driven by robust growth in the US and EU markets, whereas other core markets and ROW saw subdued performance.
- Recent product launches, along with volume growth in existing products, boosted US and EU performance for the quarter.
- The performance of other core markets and ROW was muted due to a lower offtake for certain products.
- Cenexi has been slightly EBITDA positive for the past three quarters now and is expected to reach high-single-digit EBITDA margin in FY27E.
- GLAND recently announced an agreement with a global pharma company, under which the manufacturing would be done from Gland's site and subsequent packaging would be done from Cenexi site, providing full-service CDMO work.
- We raise our earnings estimates by 3%/4% for FY27/FY28, factoring in: a) a healthy pace of differentiated product launches in the US and European markets, and b) currency depreciation tailwinds.
- We value GLAND at 30x 12-month forward earnings to arrive at a TP of INR3,080. We expect a 21% earnings CAGR over FY26-28 on the back of complex injectables, peptides, GLP-1 and liposomal technologies, rather than conventional sterile manufacturing. **Reiterate BUY**.

Healthy revenue growth; operating leverage drives margins YoY

- 1QFY27 revenue grew 19.6% YoY to INR18b (our estimate: INR17.1b).
- Gross margin (GM) remained stable YoY at 65.3%.
- EBITDA margin expanded 275bp YoY to 27.2% (our estimate: 26.3%) as staff expenses/other expenses fell 245bp/40bp as % of sales.
- EBITDA grew 33% YoY to INR4.9b (our estimate: INR4.5b).
- Adj. PAT grew 47% YoY to INR3.2b (our estimate: INR2.9b).

US, Europe outshine; India/ROW/other core markets underperform

- US sales grew 32% YoY to INR9.8b (54% of sales).
- Europe sales grew 20% YoY to INR3.9b (22% of sales).
- India sales grew 12% YoY to INR666m (4% of sales).
- ROW sales grew 2% YoY to INR3b (17% of sales).
- Other core markets declined 28% YoY to INR534m (3% of sales).

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com) | **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)
Vipul Mehta - Research Analyst (vipul.mehta@motilaloswal.com) | **Khyati Sonthalia - Research Analyst** (khyati.sonthalia@motilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- GLAND guided for revenue growth of 15-16% YoY in FY27 in CC terms and aspires to achieve a 20% CAGR from FY28 onward over next four years.
- Revenue growth would be driven by the scale-up of recently signed contracts and a higher off-take of base products, supported by better capacity utilization.
- Base business (Ex-Cenexi) grew by 24% YoY. ~5% YoY growth in revenue was driven by favorable currency movements.
- While Gland already had an agreement in place with Neuland, the recent agreement adds 5-6 products and would require an additional manufacturing suite.
- Cenexi revenue/EBITDA stood at EUR48m (flat YoY)/EUR2m in 1QFY27.
- Technology transfer with respect to a recent strategic manufacturing agreement with a global MNC should begin from Sep'26, with the initial product basket to be transferred over 24 months.
- For the strategic agreement, ~60% of products are US-focused, 30-35% Europe and the balance RoW. Cenexi will support warehousing, packaging and the final release for select European products, enabling Gland to offer an end-to-end global supply solution.

Consolidated - Quarterly Earning

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	Var (%)
Net Sales	**15,056**	**14,869**	**16,954**	**17,428**	**18,003**	**17,370**	**18,491**	**18,724**	**64,307**	**72,587**	**17,075**	**5.4**
YoY Change (%)	7.4	5.8	22.5	22.3	19.6	16.8	9.1	7.4	14.5	12.9	13.4	
Total Expenditure	11,378	11,730	12,605	12,298	13,109	12,645	13,591	13,724	48,011	53,070	12,584	
EBITDA	**3,678**	**3,139**	**4,349**	**5,130**	**4,894**	**4,725**	**4,900**	**4,999**	**16,296**	**19,518**	**4,491**	**9.0**
YoY Change (%)	39.1	5.7	20.8	47.6	33.1	50.5	12.7	-2.6	28.4	19.8	22.1	
Margins (%)	24.4	21.1	25.7	29.4	27.2	27.2	26.5	26.7	25.3	26.9	26.3	
Depreciation	1,011	1,063	1,076	1,087	1,113	1,086	1,156	1,171	4,237	4,526	1,085	
Interest	115	78	39	100	44	43	43	43	333	171	85	
Other Income	575	842	632	1,115	612	661	649	674	3,163	2,596	756	
PBT before EO expense	**3,128**	**2,839**	**3,865**	**5,058**	**4,350**	**4,257**	**4,350**	**4,460**	**14,890**	**17,417**	**4,077**	
One-off income/(expense)	0	0	243	0	0	0	0	0	243	0	0	
PBT	**3,128**	**2,839**	**3,621**	**5,058**	**4,350**	**4,257**	**4,350**	**4,460**	**14,646**	**17,417**	**4,077**	
Tax	973	1,002	1,007	1,391	1,180	1,171	1,188	1,213	4,373	4,752	1,174	
Rate (%)	31.1	35.3	27.8	27.5	27.1	27.5	27.3	27.2	29.9	27.3	28.8	
Reported PAT	**2,155**	**1,837**	**2,615**	**3,667**	**3,170**	**3,087**	**3,162**	**3,247**	**10,273**	**12,665**	**2,903**	
Adj PAT	**2,155**	**1,837**	**2,791**	**3,667**	**3,170**	**3,087**	**3,162**	**3,247**	**10,449**	**12,665**	**2,903**	**9.2**
YoY Change (%)	49.9	12.3	36.3	96.6	47.1	68.0	13.3	-11.5	49.6	21.2	34.7	
Margins (%)	14.3	12.4	16.5	21.0	17.6	17.8	17.1	17.3	16.2	17.4	17.0	
EPS	**13.1**	**11.2**	**16.9**	**22.3**	**19.2**	**18.7**	**19.2**	**19.7**	**63.4**	**76.9**	**18**	

E: MOFSL Estimates



Management call highlights

- Gland plan to discontinue older ampoule lines at Fontenay and replace it with a new high-capacity line, expected to enter production in early 2027 and add annual capacity of ~30m.
- Capex during the quarter stood at INR1.1b.
- Reiterated Cenexi revenue guidance of ~EUR200m and high-single-digit EBITDA margin for FY27.
- Gland plans to spend capex of INR5.5b in FY27. Capex of ~INR1.6b is allocated for an isolated line in the oncology plant. Gland is adding a PFS line and an ophthalmology line at the Pashamylaram site to cater to increased volume demand.
- GLP-1 opportunity can pan out meaningfully from FY30 onward for Gland in the US and EU markets. Canada market could be an interesting opportunity next year onward.

Strong base business growth partially offset by flat Cenexi performance

US markets - Volume expansion/new launches supported growth

- US sales grew 32% YoY to INR9.8b (54% of sales), driven by recent product launches from the CDMO segment and volume expansion in existing products.
- The CDMO division delivered 48% YoY growth to INR2.6b (27% of US sales), driven by recent product launches, Dalbavancin and Multi-VMN.
- The B2B division delivered 27% YoY growth to INR7.1b (73% of US sales), driven by volume expansion in Enoxaparin/Vancomycin/Chlorothiazide and Heparin.
- During the quarter, the company launched four molecules in the US.
- GLAND filed three ANDAs and received seven approvals, taking the cumulative US filings to 389, of which 342 have been approved, reinforcing the sustainability of the pipeline.

Europe markets – CDMO led growth; licensing opportunities to strengthen outlook

- Europe market posted 20% YoY growth to INR3.9b (22% of sales), supported by volume expansion in existing products, including Daptomycin, Cenexi CDMO products and recent product launch, Dalbavancin.
- CDMO/B2B divisions delivered 20%/6% YoY growth to INR3.9b/INR38m.
- GLAND continues to strengthen its presence in Europe via differentiated products, expanded customer relationships and improved commercial execution.
- It has licensed multiple products from various partners across several European countries, while active discussions with additional customers are underway, providing scope for further product additions and growth in the region.
- Cenexi's European manufacturing capabilities further strengthen Gland's ability to offer end-to-end solution to customers, for products requiring local warehousing, packaging and final release.

ROW markets – Near-term impact due to tender delays

- The ROW market posted 2% YoY growth to INR3b (17% of sales), impacted by stable YoY performance in CDMO segment at INR1.7b. However, B2B segment grew 6% YoY to INR1.4b.


- Management indicated that demand across several key ROW markets remained healthy, but performance was impacted by supply disruptions in Saudi Arabia.

On overall basis, we expect a 14% sales CAGR over FY26-28 to INR59.8b, backed by strong performance in US/Europe markets, supported by differentiated launch pipeline and CDMO contracts.

Reiterate BUY


- We raise our earnings estimates by 3%/4% for FY27/FY28, factoring in: a) a healthy pace of differentiated product launches in US/Europe markets, and b) currency depreciation tailwinds.
- We value GLAND at 30x 12M forward earnings to arrive at a TP of INR3,080. We expect a 21% earnings CAGR over FY26-28 on the back of complex injectables, peptides, GLP-1 and liposomal technologies, rather than conventional sterile manufacturing. **Reiterate BUY.**

Exhibit 1: P/E chart



Source: MOFSL, Company, Bloomberg

Exhibit 2: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg

Story in charts

Exhibit 3: Expect 14% revenue CAGR over FY26-28




Exhibit 4: Expect 13% core market sales CAGR over FY26-28




Exhibit 5: Expect RoW sales to post 18% CAGR over FY26-28




Exhibit 6: Expect India sales to post a 9% CAGR over FY26-28






Exhibit 7: EBITDA margin to expand 260bp over FY26-28



Source: Company, MOFSL

Exhibit 8: Expect EPS CAGR of 21% over FY26-28



Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement							(INRm)
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Total Income from Operations	**44,007**	**36,246**	**56,647**	**56,165**	**64,307**	**72,587**	**83,166**
Change (%)	27.1	-17.6	56.3	-0.9	14.5	12.9	14.6
Total Expenditure	**28,906**	**25,888**	**43,138**	**43,476**	**48,011**	**53,070**	**59,949**
% of Sales	65.7	71.4	76.2	77.4	74.7	73.1	72.1
EBITDA	**15,102**	**10,358**	**13,509**	**12,689**	**16,296**	**19,518**	**23,218**
Margin (%)	34.3	28.6	23.8	22.6	25.3	26.9	27.9
Depreciation	1,103	1,467	3,446	3,779	4,237	4,526	4,816
EBIT	**13,999**	**8,890**	**10,063**	**8,910**	**12,059**	**14,992**	**18,402**
Int. and Finance Charges	52	74	262	420	333	171	170
Other Income	2,239	2,405	1,702	2,136	3,163	2,596	2,696
PBT bef. EO Exp.	**16,186**	**11,220**	**11,503**	**10,626**	**14,890**	**17,417**	**20,928**
EO Items	0	-685	178	0	-243	0	0
PBT after EO Exp.	**16,186**	**10,536**	**11,325**	**10,626**	**14,646**	**17,417**	**20,928**
Total Tax	4,069	2,735	3,601	3,641	4,373	4,752	5,571
Tax Rate (%)	25.1	26.0	31.8	34.3	29.9	27.3	26.6
Minority Interest	0	0	0	0	0	0	0
Reported PAT	**12,117**	**7,800**	**7,724**	**6,985**	**10,273**	**12,665**	**15,357**
Adjusted PAT	**12,117**	**8,307**	**7,839**	**6,985**	**10,449**	**12,665**	**15,357**
Change (%)	21.5	-31.4	-5.6	-10.9	49.6	21.2	21.3
Margin (%)	26.2	21.5	13.4	12.0	15.5	16.8	17.9

Consolidated - Balance Sheet							(INRm)
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Equity Share Capital	164	165	165	165	165	165	165
Total Reserves	71,412	79,423	87,074	91,343	103,415	116,080	131,437
Net Worth	**71,576**	**79,587**	**87,238**	**91,507**	**103,580**	**116,245**	**131,602**
Minority Interest	0	0	0	0	0	0	0
Total Loans	46	45	3,722	3,137	2,836	2,836	2,836
Deferred Tax Liabilities	878	842	1,697	1,627	1,520	1,520	1,520
Capital Employed	**72,499**	**80,473**	**92,656**	**96,272**	**107,935**	**120,600**	**135,957**
Gross Block	20,910	23,061	47,846	53,570	60,800	65,287	68,485
Less: Accum. Deprn.	5,888	7,355	10,801	14,580	18,816	23,342	28,158
Net Fixed Assets	**15,022**	**15,705**	**37,045**	**38,990**	**41,983**	**41,945**	**40,327**
Goodwill on Consolidation	0	0	2,423	2,482	2,939	2,939	2,939
Capital WIP	1,907	1,772	2,379	1,506	3,422	2,434	1,737
Total Investments	**1,549**	**0**	**6,559**	**0**	**0**	**0**	**0**
Curr. Assets, Loans&Adv.	**59,858**	**70,298**	**57,703**	**68,751**	**76,140**	**89,632**	**109,500**
Inventory	11,857	19,453	16,552	16,852	17,439	21,083	23,815
Account Receivables	11,988	8,714	15,587	15,165	18,914	20,881	23,925
Cash and Bank Balance	30,934	37,707	18,394	25,562	33,591	36,780	49,285
Loans and Advances	5,079	4,424	7,169	11,171	6,196	10,888	12,475
Curr. Liability & Prov.	**5,836**	**7,302**	**13,451**	**15,456**	**16,549**	**16,350**	**18,545**
Account Payables	4,629	5,874	8,627	9,314	8,339	11,632	13,139
Other Current Liabilities	960	1,115	2,863	4,173	5,713	2,903	3,327
Provisions	248	313	1,961	1,969	2,498	1,815	2,079
Net Current Assets	**54,022**	**62,997**	**44,252**	**53,294**	**59,591**	**73,282**	**90,954**
Appl. of Funds	**72,499**	**80,473**	**92,656**	**96,271**	**107,935**	**120,600**	**135,957**

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)							
Adj. EPS	**73.6**	**50.4**	**47.6**	**42.4**	**63.4**	**76.9**	**93.2**
Cash EPS	80.5	59.3	68.5	65.3	89.1	104.3	122.4
BV/Share	435.6	483.2	529.7	555.4	628.7	705.5	798.7
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)							
P/E	36.2	52.8	56.0	62.8	42.0	34.6	28.6
Cash P/E	33.1	44.9	38.9	40.8	29.9	25.5	21.8
P/BV	6.1	5.5	5.0	4.8	4.2	3.8	3.3
EV/Sales	9.2	11.1	7.5	7.4	6.3	5.6	4.7
EV/EBITDA	26.9	38.7	31.4	32.8	25.0	20.7	16.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	16.4	8.6	36.4	31.6	32.6	4.6	60.6
Return Ratios (%)							
RoE	18.6	11.0	9.4	7.8	10.7	11.5	12.4
RoCE	18.6	11.1	9.4	7.8	10.6	11.3	12.2
RoIC	32.5	16.6	12.9	8.7	12.1	14.3	16.2
Working Capital Ratios							
Asset Turnover (x)	2.1	1.6	1.2	1.0	1.1	1.1	1.2
Inventory (Days)	98	196	107	110	99	106	105
Debtor (Days)	99	88	100	99	107	105	105
Creditor (Days)	38	59	56	61	47	58	58
Leverage Ratio (x)							
Net Debt/Equity	-0.45	-0.47	-0.2	-0.2	-0.3	-0.3	-0.4

Consolidated - Cash Flow Statement (INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	16,186	10,546	11,325	10,627	14,646	17,417	20,928
Depreciation	1,103	1,467	3,446	3,779	4,237	4,526	4,816
Interest & Finance Charges/ (Income)	-1,352	-1,731	-1,288	-2,043	333	-2,425	-2,526
Direct Taxes Paid	-4,065	-3,109	-3,062	3,538	-4,555	-4,752	-5,571
(Inc)/Dec in WC	-3,930	-4,179	-532	-61	-2,545	-10,502	-5,167
CF from Operations	**7,941**	**2,994**	**9,889**	**15,840**	**12,116**	**4,264**	**12,479**
Others	-33	646	79	-6,693	-1,802	0	0
CF from Operating incl EO	**7,908**	**3,640**	**9,968**	**9,147**	**10,314**	**4,264**	**12,479**
(Inc)/Dec in FA	-5,217	-2,230	-3,975	-3,938	-4,938	-3,500	-2,500
Free Cash Flow	**2,691**	**1,410**	**5,993**	**5,209**	**5,376**	**764**	**9,979**
(Pur)/Sale of Investments	-1,504	1,577	4	12	33	0	0
Others	-3,272	12,764	-13,521	20,973	6,283	2,596	2,696
CF from Investments	**-9,993**	**12,112**	**-17,492**	**17,047**	**1,377**	**-904**	**196**
Issue of Shares	386	215	5	25	0	0	0
Inc/(Dec) in Debt	-3	-3	-7,743	-759	-712	0	0
Interest Paid	-34	-63	-256	-306	-492	-171	-170
Dividend Paid	0	0	0	-3,295	0	0	0
CF from Fin. Activity	**349**	**149**	**-7,994**	**-4,335**	**-4,170**	**-171**	**-170**
Inc/Dec of Cash	**-1,736**	**15,901**	**-15,518**	**21,860**	**7,522**	**3,189**	**12,505**
Opening Balance	4,925	3,188	19,089	3,571	25,430	32,952	36,141
Closing Balance	**3,188**	**19,089**	**3,571**	**25,430**	**32,952**	**36,141**	**48,646**
Term Deposit with Banks/Forex	27,746	18,618	14,823	132	639	639	639
Total Cash & Cash Eq	**30,934**	**37,707**	**18,394**	**25,562**	**33,591**	**36,780**	**49,285**

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

.

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

****

The associates of MOFSL may have:
financial interest in the subject company
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
received compensation/other benefits from the subject company in the past 12 months
any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
Served subject company as its clients during twelve months preceding the date of distribution of the research report.
The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.